KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) Gross Margin (2020 - 2025)

Ginkgo Bioworks Holdings' Gross Margin history spans 6 years, with the latest figure at 55.68% for Q4 2025.

  • For Q4 2025, Gross Margin fell 5329.0% year-over-year to 55.68%; the TTM value through Dec 2025 reached 80.93%, down 1120.0%, while the annual FY2025 figure was 83.02%, 1698.0% down from the prior year.
  • Gross Margin reached 55.68% in Q4 2025 per DNA's latest filing, down from 78.95% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 108.96% in Q4 2024 to a low of 144.25% in Q1 2023.
  • Average Gross Margin over 5 years is 17.39%, with a median of 42.01% recorded in 2022.
  • Peak YoY movement for Gross Margin: plummeted -17259bps in 2023, then soared 24425bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 21.74% in 2021, then soared by 103bps to 0.56% in 2022, then skyrocketed by 17770bps to 100.0% in 2023, then increased by 9bps to 108.96% in 2024, then tumbled by -49bps to 55.68% in 2025.
  • Per Business Quant, the three most recent readings for DNA's Gross Margin are 55.68% (Q4 2025), 78.95% (Q3 2025), and 89.15% (Q2 2025).